TABLE 3

Estimated prevalences of ARV TF in plasma, DBS, and DPS using the CAP/CTM

Reason for VL testing and ARV TF diagnostic threshold usedPrevalence (95% CI) of TF with:P valuea
PlasmabDBScDPSdPlasma-DBSPlasma-DPS
Overall
    5,000 copies/ml0.18 (0.16–0.21)0.55 (0.51–0.58)0.19 (0.16–0.23)<.0010.38
    1,000 copies/ml0.23 (0.21–0.26)0.80 (0.77–0.83)0.27 (0.23–0.31)<.0010.71
Routine
    5,000 copies/ml0.18 (0.15–0.22)0.51 (0.47–0.56)0.18 (0.14–0.22)<.0010.21
    1,000 copies/ml0.22 (0.18–0.25)0.80 (0.76–0.82)0.25 (0.20–0.30)<.0010.28
Targeted
    5,000 copies/ml0.18 (0.14–0.22)0.58 (0.53–0.64)0.21 (0.16–0.26)<.0011
    1,000 copies/ml0.25 (0.21–0.30)81.5 (0.77–0.86)0.30 (0.24–0.35)<.0011
  • a Difference between prevalence estimates in plasma-DBS or plasma-DPS pairs tested for significance using McNemar's test for paired proportions.

  • b n = 838.

  • c n = 823.

  • d n = 546.